Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2000 May;59(5):321–325. doi: 10.1136/ard.59.5.321

Inflammation-mediated rheumatic diseases and atherosclerosis

S MANZI 1, M C WASKO 1, S MANZI 1
PMCID: PMC1753135  PMID: 10784507

Full Text

The Full Text of this article is available as a PDF (126.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbot S. E., Kaul A., Stevens C. R., Blake D. R. Isolation and culture of synovial microvascular endothelial cells. Characterization and assessment of adhesion molecule expression. Arthritis Rheum. 1992 Apr;35(4):401–406. doi: 10.1002/art.1780350407. [DOI] [PubMed] [Google Scholar]
  2. Arnalich F., Benito-Urbina S., Gonzalez-Gancedo P., Iglesias E., de Miguel E., Gijon-Baños J. Inadequate production of progesterone in women with systemic lupus erythematosus. Br J Rheumatol. 1992 Apr;31(4):247–251. doi: 10.1093/rheumatology/31.4.247. [DOI] [PubMed] [Google Scholar]
  3. Bulkley B. H., Roberts W. C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975 Feb;58(2):243–264. doi: 10.1016/0002-9343(75)90575-6. [DOI] [PubMed] [Google Scholar]
  4. Desai-Mehta A., Lu L., Ramsey-Goldman R., Datta S. K. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996 May 1;97(9):2063–2073. doi: 10.1172/JCI118643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Elinder L. S., Dumitrescu A., Larsson P., Hedin U., Frostegård J., Claesson H. E. Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vasc Biol. 1997 Oct;17(10):2257–2263. doi: 10.1161/01.atv.17.10.2257. [DOI] [PubMed] [Google Scholar]
  6. Firestein G. S. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest. 1999 Jan;103(1):3–4. doi: 10.1172/JCI5929. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Galtier-Dereure F., Biron C., Vies M., Bourgeois V., Schved J. F., Bringer J. Vascular complications of diabetes mellitus: what role for phospholipid-binding antibodies? Lupus. 1998;7(7):469–474. doi: 10.1191/096120398678920488. [DOI] [PubMed] [Google Scholar]
  8. George J., Harats D., Gilburd B., Levy Y., Langevitz P., Shoenfeld Y. Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus. 1999;8(3):220–226. doi: 10.1191/096120399678847597. [DOI] [PubMed] [Google Scholar]
  9. Gharavi A. E., Wilson W. A. The syndrome of thrombosis, thrombocytopenia, and recurrent spontaneous abortions associated with antiphospholipid antibodies: Hughes syndrome. Lupus. 1996 Oct;5(5):343–344. doi: 10.1177/096120339600500501. [DOI] [PubMed] [Google Scholar]
  10. Haagsma C. J., Blom H. J., van Riel P. L., van't Hof M. A., Giesendorf B. A., van Oppenraaij-Emmerzaal D., van de Putte L. B. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis. 1999 Feb;58(2):79–84. doi: 10.1136/ard.58.2.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hasunuma Y., Matsuura E., Makita Z., Katahira T., Nishi S., Koike T. Involvement of beta 2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages. Clin Exp Immunol. 1997 Mar;107(3):569–573. doi: 10.1046/j.1365-2249.1997.d01-948.x. [DOI] [PubMed] [Google Scholar]
  12. Hedman M., Nilsson E., de la Torre B. Low blood and synovial fluid levels of sulpho-conjugated steroids in rheumatoid arthritis. Clin Exp Rheumatol. 1992 Jan-Feb;10(1):25–30. [PubMed] [Google Scholar]
  13. Hwang S. J., Ballantyne C. M., Sharrett A. R., Smith L. C., Davis C. E., Gotto A. M., Jr, Boerwinkle E. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. Circulation. 1997 Dec 16;96(12):4219–4225. doi: 10.1161/01.cir.96.12.4219. [DOI] [PubMed] [Google Scholar]
  14. Hörkkö S., Miller E., Dudl E., Reaven P., Curtiss L. K., Zvaifler N. J., Terkeltaub R., Pierangeli S. S., Branch D. W., Palinski W. Antiphospholipid antibodies are directed against epitopes of oxidized phospholipids. Recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J Clin Invest. 1996 Aug 1;98(3):815–825. doi: 10.1172/JCI118854. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ishikawa H., Hirata S., Nishibayashi Y., Imura S., Kubo H., Ohno O. The role of adhesion molecules in synovial pannus formation in rheumatoid arthritis. Clin Orthop Relat Res. 1994 Mar;(300):297–303. [PubMed] [Google Scholar]
  16. Kannel W. B., Wolf P. A., Castelli W. P., D'Agostino R. B. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987 Sep 4;258(9):1183–1186. [PubMed] [Google Scholar]
  17. Karmann K., Hughes C. C., Schechner J., Fanslow W. C., Pober J. S. CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4342–4346. doi: 10.1073/pnas.92.10.4342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Koshy M., Berger D., Crow M. K. Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest. 1996 Aug 1;98(3):826–837. doi: 10.1172/JCI118855. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Lahita R. G., Bradlow H. L., Kunkel H. G., Fishman J. Increased 16 alpha-hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab. 1981 Jul;53(1):174–178. doi: 10.1210/jcem-53-1-174. [DOI] [PubMed] [Google Scholar]
  20. Lahita R. G., Kunkel H. G., Bradlow H. L. Increased oxidation of testosterone in systemic lupus erythematosus. Arthritis Rheum. 1983 Dec;26(12):1517–1521. doi: 10.1002/art.1780261215. [DOI] [PubMed] [Google Scholar]
  21. Lahita R. G. The connective tissue diseases and the overall influence of gender. Int J Fertil Menopausal Stud. 1996 Mar-Apr;41(2):156–165. [PubMed] [Google Scholar]
  22. Lozada C., Levin R. I., Huie M., Hirschhorn R., Naime D., Whitlow M., Recht P. A., Golden B., Cronstein B. N. Identification of C1q as the heat-labile serum cofactor required for immune complexes to stimulate endothelial expression of the adhesion molecules E-selectin and intercellular and vascular cell adhesion molecules 1. Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8378–8382. doi: 10.1073/pnas.92.18.8378. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Mach F., Schönbeck U., Sukhova G. K., Atkinson E., Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998 Jul 9;394(6689):200–203. doi: 10.1038/28204. [DOI] [PubMed] [Google Scholar]
  24. Manzi S., Meilahn E. N., Rairie J. E., Conte C. G., Medsger T. A., Jr, Jansen-McWilliams L., D'Agostino R. B., Kuller L. H. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol. 1997 Mar 1;145(5):408–415. doi: 10.1093/oxfordjournals.aje.a009122. [DOI] [PubMed] [Google Scholar]
  25. Manzi S., Selzer F., Sutton-Tyrrell K., Fitzgerald S. G., Rairie J. E., Tracy R. P., Kuller L. H. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Jan;42(1):51–60. doi: 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D. [DOI] [PubMed] [Google Scholar]
  26. Mendelsohn M. E., Karas R. H. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999 Jun 10;340(23):1801–1811. doi: 10.1056/NEJM199906103402306. [DOI] [PubMed] [Google Scholar]
  27. Monson R. R., Hall A. P. Mortality among arthritics. J Chronic Dis. 1976 Jul;29(7):459–467. doi: 10.1016/0021-9681(76)90086-2. [DOI] [PubMed] [Google Scholar]
  28. Moreland L. W., Heck L. W., Jr, Koopman W. J. Biologic agents for treating rheumatoid arthritis. Concepts and progress. Arthritis Rheum. 1997 Mar;40(3):397–409. doi: 10.1002/art.1780400302. [DOI] [PubMed] [Google Scholar]
  29. Morgan S. L., Baggott J. E., Lee J. Y., Alarcón G. S. Folic acid supplementation prevents deficient blood folate levels and hyperhomocysteinemia during longterm, low dose methotrexate therapy for rheumatoid arthritis: implications for cardiovascular disease prevention. J Rheumatol. 1998 Mar;25(3):441–446. [PubMed] [Google Scholar]
  30. Moulton K. S., Heller E., Konerding M. A., Flynn E., Palinski W., Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation. 1999 Apr 6;99(13):1726–1732. doi: 10.1161/01.cir.99.13.1726. [DOI] [PubMed] [Google Scholar]
  31. Mutru O., Koota K., Isomäki H. Causes of death in autopsied RA patients. Scand J Rheumatol. 1976;5(4):239–240. doi: 10.3109/03009747609099912. [DOI] [PubMed] [Google Scholar]
  32. Mutru O., Laakso M., Isomäki H., Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Cardiology. 1989;76(1):71–77. doi: 10.1159/000174474. [DOI] [PubMed] [Google Scholar]
  33. Myllykangas-Luosujärvi R., Aho K., Kautiainen H., Isomäki H. Cardiovascular mortality in women with rheumatoid arthritis. J Rheumatol. 1995 Jun;22(6):1065–1067. [PubMed] [Google Scholar]
  34. Pasceri V., Yeh E. T. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation. 1999 Nov 23;100(21):2124–2126. doi: 10.1161/01.cir.100.21.2124. [DOI] [PubMed] [Google Scholar]
  35. Petri M., Perez-Gutthann S., Spence D., Hochberg M. C. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med. 1992 Nov;93(5):513–519. doi: 10.1016/0002-9343(92)90578-y. [DOI] [PubMed] [Google Scholar]
  36. Petri M., Roubenoff R., Dallal G. E., Nadeau M. R., Selhub J., Rosenberg I. H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 1996 Oct 26;348(9035):1120–1124. doi: 10.1016/S0140-6736(96)03032-2. [DOI] [PubMed] [Google Scholar]
  37. Pruzanski W., Goulding N. J., Flower R. J., Gladman D. D., Urowitz M. B., Goodman P. J., Scott K. F., Vadas P. Circulating group II phospholipase A2 activity and antilipocortin antibodies in systemic lupus erythematosus. Correlative study with disease activity. J Rheumatol. 1994 Feb;21(2):252–257. [PubMed] [Google Scholar]
  38. Puurunen M., Mänttäri M., Manninen V., Tenkanen L., Alfthan G., Ehnholm C., Vaarala O., Aho K., Palosuo T. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med. 1994 Nov 28;154(22):2605–2609. [PubMed] [Google Scholar]
  39. Ridker P. M., Cushman M., Stampfer M. J., Tracy R. P., Hennekens C. H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 Apr 3;336(14):973–979. doi: 10.1056/NEJM199704033361401. [DOI] [PubMed] [Google Scholar]
  40. Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999 Jan 14;340(2):115–126. doi: 10.1056/NEJM199901143400207. [DOI] [PubMed] [Google Scholar]
  41. Roubenoff R., Dellaripa P., Nadeau M. R., Abad L. W., Muldoon B. A., Selhub J., Rosenberg I. H. Abnormal homocysteine metabolism in rheumatoid arthritis. Arthritis Rheum. 1997 Apr;40(4):718–722. doi: 10.1002/art.1780400418. [DOI] [PubMed] [Google Scholar]
  42. Roubey R. A. Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other "antiphospholipid" autoantibodies. Blood. 1994 Nov 1;84(9):2854–2867. [PubMed] [Google Scholar]
  43. Selhub J., Jacques P. F., Bostom A. G., D'Agostino R. B., Wilson P. W., Belanger A. J., O'Leary D. H., Wolf P. A., Schaefer E. J., Rosenberg I. H. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995 Feb 2;332(5):286–291. doi: 10.1056/NEJM199502023320502. [DOI] [PubMed] [Google Scholar]
  44. Stampfer M. J., Malinow M. R., Willett W. C., Newcomer L. M., Upson B., Ullmann D., Tishler P. V., Hennekens C. H. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA. 1992 Aug 19;268(7):877–881. [PubMed] [Google Scholar]
  45. Thompson S. G., Kienast J., Pyke S. D., Haverkate F., van de Loo J. C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 1995 Mar 9;332(10):635–641. doi: 10.1056/NEJM199503093321003. [DOI] [PubMed] [Google Scholar]
  46. Torre-Amione G., Bozkurt B., Deswal A., Mann D. L. An overview of tumor necrosis factor alpha and the failing human heart. Curr Opin Cardiol. 1999 May;14(3):206–210. doi: 10.1097/00001573-199905000-00003. [DOI] [PubMed] [Google Scholar]
  47. Tsai J. C., Perrella M. A., Yoshizumi M., Hsieh C. M., Haber E., Schlegel R., Lee M. E. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6369–6373. doi: 10.1073/pnas.91.14.6369. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Urowitz M. B., Bookman A. A., Koehler B. E., Gordon D. A., Smythe H. A., Ogryzlo M. A. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 Feb;60(2):221–225. doi: 10.1016/0002-9343(76)90431-9. [DOI] [PubMed] [Google Scholar]
  49. Vaarala O., Alfthan G., Jauhiainen M., Leirisalo-Repo M., Aho K., Palosuo T. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993 Apr 10;341(8850):923–925. doi: 10.1016/0140-6736(93)91213-6. [DOI] [PubMed] [Google Scholar]
  50. Vaarala O., Mänttäri M., Manninen V., Tenkanen L., Puurunen M., Aho K., Palosuo T. Anti-cardiolipin antibodies and risk of myocardial infarction in a prospective cohort of middle-aged men. Circulation. 1995 Jan 1;91(1):23–27. doi: 10.1161/01.cir.91.1.23. [DOI] [PubMed] [Google Scholar]
  51. Vaarala O., Puurunen M., Lukka M., Alfthan G., Leirisalo-Repo M., Aho K., Palosuo T. Affinity-purified cardiolipin-binding antibodies show heterogeneity in their binding to oxidized low-density lipoprotein. Clin Exp Immunol. 1996 May;104(2):269–274. doi: 10.1046/j.1365-2249.1996.21728.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Wallberg-Jonsson S., Ohman M. L., Dahlqvist S. R. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol. 1997 Mar;24(3):445–451. [PubMed] [Google Scholar]
  53. Ward M. M. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999 Feb;42(2):338–346. doi: 10.1002/1529-0131(199902)42:2<338::AID-ANR17>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  54. Witztum J. L. The oxidation hypothesis of atherosclerosis. Lancet. 1994 Sep 17;344(8925):793–795. doi: 10.1016/s0140-6736(94)92346-9. [DOI] [PubMed] [Google Scholar]
  55. Wolfe F., Mitchell D. M., Sibley J. T., Fries J. F., Bloch D. A., Williams C. A., Spitz P. W., Haga M., Kleinheksel S. M., Cathey M. A. The mortality of rheumatoid arthritis. Arthritis Rheum. 1994 Apr;37(4):481–494. doi: 10.1002/art.1780370408. [DOI] [PubMed] [Google Scholar]
  56. Wu R., Huang Y. H., Elinder L. S., Frostegård J. Lysophosphatidylcholine is involved in the antigenicity of oxidized LDL. Arterioscler Thromb Vasc Biol. 1998 Apr;18(4):626–630. doi: 10.1161/01.atv.18.4.626. [DOI] [PubMed] [Google Scholar]
  57. Wu R., Nityanand S., Berglund L., Lithell H., Holm G., Lefvert A. K. Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol. 1997 Nov;17(11):3159–3163. doi: 10.1161/01.atv.17.11.3159. [DOI] [PubMed] [Google Scholar]
  58. Wu R., Svenungsson E., Gunnarsson I., Andersson B., Lundberg I., Schäfer Elinder L., Frostegård J. Antibodies against lysophosphatidylcholine and oxidized LDL in patients with SLE. Lupus. 1999;8(2):142–150. doi: 10.1191/096120399678847434. [DOI] [PubMed] [Google Scholar]
  59. de la Torre B., Hedman M., Nilsson E., Olesen O., Thörner A. Relationship between blood and joint tissue DHEAS levels in rheumatoid arthritis and osteoarthritis. Clin Exp Rheumatol. 1993 Nov-Dec;11(6):597–601. [PubMed] [Google Scholar]
  60. van der Wal A. C., Becker A. E., van der Loos C. M., Das P. K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994 Jan;89(1):36–44. doi: 10.1161/01.cir.89.1.36. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES